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A multi-parameter approach for predicting prostate 
cancer
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Abstract: Urokinase plasminogen activator (uPA) and its inhibitor (PAI-1) have 
shown to be of merit as biomarkers for a variety of cancers. The objective of this 
project was to assay for uPA and PAI-1 in prostate needle biopsy tissue from 217 
patients using the FEMTELLE enzyme linked immunosorbent (ELISA) assay, and to 
examine the robustness of PAI-1 as a candidate marker in benign prostatic hyper-
plasia (BPH) and prostate cancer (PCa), as previously identified in a different cohort 
of 111 patients. These results validate the assertion that PAI-1 levels of >4.5 ng mg−1 
protein in prostate biopsies are indicative of prostate malignancy in elderly men, but 
further show that tissue from BPH patients in the 70–80 year age interval express 
significantly high levels of this marker. To address this anomaly, a malignancy 
index, derived from the concentrations of prostate-specific antigen (PSA), uPA, and 
PAI-1, and patient age is proposed. This simple index discriminates prostate tissue 
from BPH and PCa patients with concordance indices of 0.59 and 0.69 when tissues 
are taken as biopsy or transurethral resection of the prostate (TURP), respectively. 
Corresponding indices for PSA as a predictor of prostate disease were 0.67 and 0.73. 
Further evaluation of the proposed malignancy index using specimens, such as ve-
nous blood, could prove valuable in the search for non-invasive predictive assays.
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1. Introduction
Urokinase plasminogen activator (uPA) and its inhibitor, plasminogen activator inhibitor-1 (PAI-1), 
are involved in cancer invasion and metastasis (Duffy, McGowan, Harbeck, Thomssen, & Schmitt, 
2014). There is consistent proof, validated at level-of-evidence-1, from retrospective studies since 
the late 1980s, that low levels of both uPA and PAI-1 are associated with excellent prognosis in 
node-negative breast cancer, whereas high levels of either, or both, are associated with poor out-
come (Harbeck et al., 2013; Schmitt et al., 2011). No definitive role of the involvement of uPA and 
PAI-1 in prostate cancer (PCa) has emerged. It also remains uncertain whether either of these two 
components predominates in different stages of disease to highlight a distinguishing feature which 
could be used for the diagnosis or prognosis of PCa.
Initial research focusing on surgical resections of prostate tissue obtained by transurethral resec-
tion of the prostate (TURP) concluded that the uPA/PAI-1 ratio was not merely a numerical phenom-
enon but separated benign and malignant prostate pathologies, and emerged as a candidate marker 
for BPH and PCa disease (Akudugu, Serafin, & Böhm, 2015; Böhm et al., 2013). This was supported by 
several observations: that the ratios were significantly higher for PCa pathologies than for BPH pa-
thologies; that the ratio was strongly dependent upon the uPA concentration in BPH pathologies, but 
not in PCa pathologies; and that the ratio for PCa, but not for BPH cases, showed a dependence upon 
patient age (Akudugu et al., 2015; Böhm et al., 2013).
In a subsequent study using core needle prostate biopsy tissue, a number of trends emerged in 
favour of PAI-1 acting, possibly, as a sole PCa biomarker (Serafin, Böhm, Fernandez, Achel, & 
Akudugu, 2016): the separation seen between uPA/PAI-1 ratios for BPH and PCa in the study on TURP 
tissue was not apparent for biopsy tissue; uPA appeared to play a minor role as a potential marker in 
prostate biopsy tissue; in men below the age of 60 years, no difference existed in PAI-1 values in 
biopsies from PCa and BPH patients; persons older than 60 years of age, with PAI-1 values above 
4.5 ng mg−1 protein were moderately certain to have PCa; and those below the age of 60 years with 
PAI-1 values lower than 4.5 ng mg−1 protein were more likely to have BPH.
The goal of the study reported here was to validate findings from an earlier cohort of prostate bi-
opsy samples (Serafin et al., 2016). Combined, the results confirm our assertion that PAI-1 may be a 
candidate prostate biomarker, and further show a significantly raised PAI-1 level in the absence of 
prostate disease for individuals older than 70 years of age. However, what is not clear about this 
phenomenon of raised PAI-1 level is whether it is a diagnostic grey zone or due to benign prostatic 
hyperplasia (BPH) with prostatitis or other pathologies? Because of the semi-random nature of sam-
pling of the prostate during biopsy, urologists and pathologists report that initial prostate biopsy 
histopathology has a 20 to 30% chance of missing a tumour (Shariat & Roehrborn, 2008). To partly 
address this clinically relevant issue, we propose a “malignancy index” derived from four parame-
ters, namely, the concentrations of three biomarkers (prostate-specific antigen (PSA), PAI-1 and 
uPA), and patient age. We show that this index displays robustness in distinguishing between BPH 
and PCa, and may potentially serve as a reliable tool for diagnosing prostate malignancies, espe-
cially in individuals above 60 years of age.
2. Materials and methods
2.1. Patients and samples
Prostate biopsy tissue was obtained from 217 patients after signed consent, and according to ethical 
guidelines. Patients were recruited from Tygerberg Academic Hospital and the Gatesville Medical 
Centre (Cape Town, South Africa). One hundred and fourteen patients were diagnosed as PCa and 
103 as BPH, based on digital rectal examination (DRE), PSA, Gleason score and histopathology, as 
described elsewhere (Böhm et al., 2013; Serafin et al., 2016). An abnormal PSA and/or DRE finding 
resulted in an 8 core transrectal prostate biopsy. A histology positive score was added to the PSA and 
DRE scores to obtain a 10-point final score. For example, patients with a negative DRE, a PSA value 
of 4 μg L−1 and one positive core (cT1) were given a rating of 1, indicating a low probability of PCa and 
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a high probability of BPH. A distinctly abnormal DRE with a PSA value of 100 μg L−1, and one or more 
positive cores received a rating of 10, indicating a high probability of PCa and a low probability of 
BPH. Due to an unvalidated scoring system only patients with a score of 8 or higher, in the PCa cat-
egory, were included. In order to reduce errors, a second urologist reviewed the clinical data and 
scores of patients. The objective of the scoring system was to obtain a high level of certainty of PCa 
identification with a low probability of missing same.
The average ages of the PCa and BPH groups were 66.3 years (range: 46–86 years) and 64.0 years 
(range: 41–85 years), respectively. Corresponding PSA concentrations for the patient groups emerged 
as 77 ng mL−1 (range: 0.67–1526 ng mL−1) and 11 ng mL−1 (range: 0.40–69 ng mL−1). The project was 
approved (reference N09/11/330) by the Ethics Committee of the Faculty of Medicine and Health 
Sciences at the University of Stellenbosch (South Africa), and conducted in accordance with the 
Helsinki Declaration of 1975.
2.2. Sample preparation and measurement of PAI-1 and uPA content
For protein extraction, prostate biopsy tissue samples were placed in cold extraction buffer, com-
posed of 240 μL pH 8.5 Tris-buffered saline and 10 μL of 25% Triton X-100 (Sekisui Diagnostics 
Product R22), at 4°C for 24 h on a rotating roller, followed by centrifugation at 20,000×g for 20 min 
at 4°C. The total protein concentration of the extracts was measured by means of the Pierce 
Bicinchoninic acid (BCA) assay (Thermo Scientific, Rockford, USA). Briefly, the total protein concen-
tration is manifest by a colour change in the sample solution from green to purple in proportion to 
protein concentration, which is then measured using a colorimetric technique. Determination of the 
PAI-1 and uPA content in the biopsy tissue samples was by the FEMTELLE enzyme linked immuno-
sorbent (ELISA) assay (Sekisui Diagnostics, LLC, Lexington, MA, USA), as described elsewhere (Jänicke 
et al., 1994). Total protein was expressed as mg mL−1, while the content of PAI-1 and uPA was ex-
pressed in ng mg−1 total protein. These data were used to test the robustness of PAI-1 as a predictor 
of prostate disease as suggested previously (Serafin et al., 2016). The results showed that some of 
the BPH patients had surprisingly high levels of PAI-1, in contrast to earlier findings (Serafin et al., 
2016). Given that we did not have access to prostate volumes for this cohort of patients, we could 
not attribute this anomaly to prostate size, as suggested elsewhere (Gondek et al., 2014). Therefore, 
we propose a new multi-parameter approach for distinguishing between BPH and PCa. For the latter, 
a malignancy index (in units of mal: 1 mal = 1 ng3 (mg protein)−2 ml−1 y−1) was derived for each pa-
tient from the concentrations of PSA, uPA and PAI-1, as follows:
3. Statistical analysis
Statistical analyses were performed using the GraphPad Prism computer program (GraphPad Software, 
San Diego, CA, USA). To compare two data-sets, the unpaired t test was used. The p-values were calcu-
lated from two-sided tests. A p-value of <0.05 indicates a statistically significant difference between 
the data sets. The predictive powers of the proposed malignancy index and PSA level were assessed 
using receiver operating characteristic (ROC) analysis. Briefly, cut-off points were chosen within the 
ranges of indices and PSA levels above which patients would have PCa. By moving the cut-off points 
across the data ranges, an array of true positive rates (sensitivity) and corresponding false positive 
rates (1-specificity) were generated from which the ROC curves were constructed. The accuracy of 
prediction was measured by the concordance statistic (c-index) representing the area under the ROC 
curve (AUC). An area of 1.0 represents a perfect prediction, while an area of 0.5 represents a 
 non-discriminating test.
Malignancy index =
[
PSA
]
∗
[
uPA
]
∗ [PAI − 1]
Age
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4. Results
4.1. PAI-1 expression in core needle biopsies of the prostate
Figure 1(A) represents the recovery of the PAI-1 marker from 111 biopsies from two groups of pa-
tients diagnosed as BPH and PCa (Serafin et al., 2016). PAI-1 levels in patients diagnosed as BPH fall 
below a cut-off range of 4.5 ng mg−1 protein across an age span of 48–73 years, whereas patients 
diagnosed as PCa show an upward trend (2.6–9.1 ng mg−1 protein) across an age span of 56–75 years. 
Figure 1(B) represents the validation assessment of 217 prostate needle biopsy samples (114 diag-
nosed as PCa, and 103 diagnosed as BPH). PAI-1 values from the PCa samples, as before, showed an 
upward trend (3.8–9.6 ng mg−1 protein) above a cut-off range of 4.5 ng mg−1 protein, across an age 
span of 55–76 years. PAI-1 values from the BPH samples are consistent with those seen previously 
for mean ages up to 65 years, and are not significantly higher than 4.5 ng mg−1 protein (Serafin et al., 
2016). However, at a mean age of 75 years, samples from BPH patients yield about 16 ng of PAI-1 
per mg protein, on average.
4.2. Proposed malignancy index in prostate biopsy and TURP samples as a predictive 
marker
In order to address the disparity in PAI-1 levels seen in Figure 1 for BPH patients, we propose a 
malignancy index which clearly significantly separates the two prostate pathologies of BPH and 
PCa with a p-value of 0.0182 (Figure 2(A)). In Figure 2(B), the malignancy indices obtained from 
prostate biopsies from 114 PCa patients increase with age and range from 0.86 ± 0.45 mal (for 
a mean age of 55 years) to 11.33 ± 6.02 mal (for a mean age of 76 years). The average malig-
nancy indices for the 103 BPH patients, on the other hand, appear to be independent of age and 
range between 0.12 ± 0.03 and 0.36 ± 0.20 mal across a similar age span as for the PCa 
cohort.
To further test the robustness of the proposed malignancy index, indices were derived from data 
obtained previously from a cohort of 100 TURP samples from the Tygerberg Academic Hospital, and 
the Gatesville Medical Center in Athlone, Cape Town, of which 30 were diagnosed as PCa and 70 as 
BPH (Akudugu et al., 2015), using a scoring system described elsewhere (Böhm et al., 2013). The 
mean ages of the BPH and PCa groups were 67.6 years (range 46–83 years) and 68.5 years (range 
53–88 years), respectively.
Figure 1. Plot of PAI-1 marker 
concentration in BPH and PCa 
biopsy tissues against the 
mean age of patients: (A) initial 
data (Serafin et al., 2016) and 
(B) validation data.
Notes: Numbers in parentheses 
and square brackets represent 
the size of each patient 
subgroup in each age interval 
for BPH and PCa, respectively. 
Data points are means ± SEM 
for the subgroups. Horizontal 
dashed-dotted line indicates 
the cut-off PAI-1 level above 
which patients older than 
60 years may likely have 
prostate cancer.
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Figure 3(A) shows a significantly higher malignancy index for PCa patients relative to their BPH 
counterparts (p = 0.0002). In Figure 3(B), the malignancy indices derived from TURP tissue increase 
with age and range from 2.78 ± 1.60 mal (for a mean age of 57 years) to 4.42 ± 3.36 mal (for a mean 
age of 77 years). The corresponding malignancy indices for the BPH patients, on the other hand, are 
constant (~0.1 mal) across a similar age span.
The predictive powers of the malignancy index and PSA levels are compared on the basis of ROC 
in Figure 4. The data indicate that the malignancy index has a potential to discriminate between 
patients with and without prostate disease. For biopsies, the c-indices were 0.59 and 0.67 when the 
malignancy index and PSA level were used as predictors, respectively (Figure 4(A)). For TURP tissue, 
the corresponding c-indices were found to be 0.69 and 0.73 (Figure 4(B)).
Figure 3. (A) Comparison of 
malignancy indices in TURP 
tissue from BPH (n = 70) and 
PCa (n = 30) patients. p < 0.05 
indicates a statistically 
significant difference. (B) Plot 
of malignancy index against 
the mean age of patients 
grouped in 10-year intervals.
Notes: In (A), horizontal 
lines represent the mean 
malignancy index in each 
group of patients. In (B), 
numbers in parentheses and 
square brackets represent the 
size of each patient subgroup 
in each age interval for BPH 
and PCa, respectively. Data 
points are means ± SEM for 
the subgroups. Horizontal 
dashed-dotted line indicates a 
malignancy index of 1.0 mal.
Figure 2. (A) Comparison of 
malignancy indices in biopsy 
tissue from BPH (n = 103) 
and PCa (n = 114) patients. 
p < 0.05 indicates a statistically 
significant difference. (B) Plot 
of malignancy index against 
the mean age of patients 
grouped in 10-year intervals. 
“Other” refers to data from 
individuals presenting 
with non-BPH and non-PCa 
pathologies.
Notes: In (A), horizontal 
lines represent the mean 
malignancy index in each 
group of patients. In (B), 
numbers in parentheses and 
square brackets represent the 
size of each patient subgroup 
in each age interval for BPH 
and PCa, respectively. Data 
points are means ± SEM for 
the subgroups. Horizontal 
dashed-dotted line indicates a 
malignancy index of 1.0 mal.
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5. Discussion
In a series of studies, the uPA/PAI-1 ratio in TURP tissue (Akudugu et al., 2015; Böhm et al., 2013) and 
PAI-1 level in prostate biopsy tissue (Serafin et al., 2016) were suggested as being capable of distin-
guishing between benign and malignant prostate pathology. The purpose of this study was to vali-
date the latter using a larger cohort of patients from whom biopsies were obtained. The data 
presented in Figure 1(B) corroborate the initial findings for PCa patients as shown in Figure 1(A) 
(Serafin et al., 2016). However, the average PAI-1 expression in biopsy tissue from BPH patients 
within the 70–80 year age bracket is about 2-fold higher than the initially suggested cut-off of 
4.5 ng mg−1 protein for a diagnosis of PCa (Serafin et al., 2016). This incidence of false-positivity, and 
therefore lack of specificity, weakens the capacity of PAI-1 in prostate biopsy to serve as a sole reli-
able biomarker for PCa. The current finding is not peculiar. The use of PSA as a screening tool for PCa 
is controversial because of concerns about a lack of specificity, and subsequent overtreatment. 
Despite its limitations, delayed diagnosis of PCa may lead to poor outcomes, greater health care 
costs, and a lower quality of life (Van Neste et al., 2016). As with false-positive (raised PSA in the 
absence of prostate disease) and false-negative PSA (low PSA in the presence of disease) readings, 
the possibility exists for PAI-1 levels to be raised in the absence of histologically proven PCa.
The Gleason score, often divided into three groups (6, 7, and 8–10), is very important in predicting 
the behavior of PCa, and that a biomarker separating, in particular, Gleason score (3 + 4 = 7) from 
(4 + 3 = 7), the latter having a poorer prognosis, is very important. That being said, there are publica-
tions that question the subjectivity and inter-observer variation of Gleason grading (Fournier & 
Narayan, 1993; Helin et al., 2005; Tabesh et al., 2007). Gonzalgo and colleagues investigated the 
relationship between biopsy Gleason score, the Gleason score from an entire prostate removed dur-
ing surgery, and the recurrence of PSA amongst men who were diagnosed with Gleason 7 cancer in 
a needle biopsy, and found that the vast majority (75%) of those turned out to have the less aggres-
sive type of Gleason 7 cancer (Gonzalgo et al., 2006). Nevertheless, it is important to counsel patients 
with Gleason 7 PCa on the history of the disease and treatment decisions.
The phenomenon of false-positivity or false-negativity in single marker expression, which often 
makes diagnosis of disease difficult, may be circumvented by considering multi-parameter ap-
proaches as it is likely that the interaction between biomarkers drives their capacity to reliably 
Figure 4. Comparison of ROC 
curves for malignancy index 
(Mal) and PSA level. (A) Mal 
obtained from needle biopsies 
of 217 patients. (B) Mal 
obtained from TURP tissues of 
100 patients. PSA was routinely 
measured.
Notes: AUC represents 
the concordance index of 
each test. Dashed diagonal 
(AUC = 0.5) represents a 
worthless test. Solid arrow 
indicates the range of 
specificities (≥0.85 for biopsy; 
≥0.65 for TURP tissue) within 
which both tests are equally 
sensitive.
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predict disease. Therefore, in the current study, we propose the use of a malignancy index, calculated 
by dividing the product of the concentrations of three popular markers (PSA, PAI-1 and uPA) by pa-
tient age. As may be seen, the malignancy index clearly separates BPH from malignant prostate pa-
thology in tissue from core needle biopsies, especially for individuals older than 60 years (Figure 
2(B)). It is interesting to note that malignancy indices derived from biopsy tissue from patients with 
 pathologies other than BPH and PCa are low and comparable to those for their BPH counterparts 
(Figure 2(B)). A mean malignancy index of 1.09 ± 0.44 mal was obtained for four patients (mean age: 
66 years) presenting with atrophic prostate, bladder hyperplasia, chronic prostatitis, and inflamma-
tion, suggesting that the index has the potential of reliably identifying PCa in elderly individuals.
To test the robustness of the proposed index, data from TURP tissue, previously presented in the 
uPA/PAI-1 ratio studies (Akudugu et al., 2015; Böhm et al., 2013), were used to derive indices, as 
shown in Figure 3. In addition to the clear distinction between the BPH and PCa patient groups, the 
index shows potential in separating benign from malignant tumours, regardless of age. This differs 
from the finding that it only appears to be capable of distinguishing between BPH and PCa in the el-
derly (Figure 2), suggesting that this approach may be more appropriate when evaluating TURP tis-
sue than biopsy tissue.
PSA is and has been the biomarker of choice for PCa screening. A new group of biomarkers has 
emerged, consisting of urine- and serum- and tissue-based assays (Prensner, Rubin, Wei, & Chinnaiyan, 
2012). The introduction of new biomarkers will likely supplement PSA until one is found to be superior, 
and replaces it. What are the requirements of an ideal biomarker? The ideal biomarker needs to be 
specific for a particular tumour type, sensitive, should accurately depict disease progression or re-
gression, be inexpensive, and quantifiable in biological samples. For PCa biomarkers used in early 
detection or monitoring of the disease, the candidate should be prostate-specific and able to distin-
guish between BPH and cancerous prostate tissue. In light of this, ROC analysis shows that at high 
levels of specificity, the proposed malignancy index and the commonly used PSA marker are equally 
sensitive as predictors of prostatic disease (Figure 4). High specificity is of the essence for diseases 
with severe prognoses, such as cancer, for which an ideal “rule-in” test would be required (Florkowski, 
2008). Therefore, within the ranges of specificities identified in Figure 4, malignancy index and PSA 
are equally discriminating, and the former merits further and more extensive evaluation.
The index proposed, herein, should not be confused with malignancy related indices suggested 
elsewhere (Jayson, Kohn, Kitchener, & Ledermann, 2014; Matchariyakul, Kochakarn, Chaimuangraj, 
Leenanupunth, & Lertsithichai, 2004). For instance, the malignancy risk index used for estimating the 
risk of malignant ovarian cancer is based on a combination of radiological findings, menstrual sta-
tus, and serum CA-125 concentration (Jayson et al., 2014). A second, though unvalidated, numerical 
malignancy index suggested for identifying candidates for prostate biopsy from a high risk group of 
individuals is based on age, DRE, PSA, prostate volume, and transrectal ultrasonography 
(Matchariyakul et al., 2004).
6. Conclusions
Although the assertion that PAI-1 expression in prostate biopsies is generally high in elderly PCa 
patients has been validated in a larger cohort, a significant level of false-positivity was observed. To 
address this, a simple but promising malignancy index was proposed to discriminate benign from 
malignant in prostate tissue (both biopsy and TURP), without the use of DRE, prostate volume, and 
ultrasound. It would be of significant interest to test the malignancy index described here, using 
venous blood samples from patients providing TURP or biopsy tissue samples, across different age 
groups and tumour stages.
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